Srikar Chamala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Srikar Chamala has a total of 181 co-authors. Here are the top co-authors by number of shared publications:
- William Bradley Barbazuk
University of Florida
5 shared publications Douglas E. Soltis
3 shared publicationsPamela S. Soltis
3 shared publications- Patrick S. Schnable
Department of Agronomy, Iowa State University, Ames, IA, United States
3 shared publications Petr Starostik
Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, FL, USA
3 shared publications- Richard J. A. Buggs
Royal Botanic Gardens Kew, Richmond, Surrey TW9 3AE, United Kingdom
3 shared publications
Latest Publications
- Open Access
- 6 March 2026
- Published by Oxford University Press (OUP) in JAMIA Open
- Vol. 9 (2)
Assessment of the adequacy of the Fast Healthcare Interoperability Resources (FHIR) Genomics standard for the representation of somatic testing reports
Objectives: Enabling the unambiguous communication of cancer genetic testing results and the corresponding therapeutic implications of identified genetic variants is of major clinical importance. In this report, we assess the adequacy of the Health Level Seven Fast Healthcare Interoperability Resources (FHIR) Genomics Reporting Implementation Guide, version 3 (also known as “FHIR Genomics”) for the structured communication of semantic objects typically appearing in real-world somatic testing reports. Materials and Methods: The GenomeX project team, part of the CodeX FHIR Accelerator, performed the following assessment: (1) gather a convenience sample of public somatic reports; (2) create a representative somatic report that includes a wide range of observations taken from the sample reports; and (3) structure the representative somatic report using the FHIR Genomics standard. Results: Attempted encodings were categorized into 1 of the 4 buckets: (1) full encoding possible (eg, DNA variants); (2) full encoding with potential variability (eg, therapeutic implications); (3) partial encoding (eg, genomic study details); and (4) not encoded (ie, FHIR Genomics has no explicit or acceptable semantic target, such as for coarsely granular pertinent negatives). In our sample somatic report, 47 semantic objects were noted, of which 87% had either full encoding or full encoding with potential variability. Conclusion: While dynamic real-world requirements, as exemplified by cancer genomics, often arise more rapidly than can be standardized, we conclude that the FHIR Genomics version 3 standard is sufficiently robust for the communication of current actionable somatic testing results.
- 6 March 2026
- Published by Oxford University Press (OUP) in JAMIA Open
- Vol. 9 (2)
Open AccessAssessment of the adequacy of the Fast Healthcare Interoperability Resources (FHIR) Genomics standard for the representation of somatic testing reports
Objectives: Enabling the unambiguous communication of cancer genetic testing results and the corresponding therapeutic implications of identified genetic variants is of major clinical importance. In this report, we assess the adequacy of the Health Level Seven Fast Healthcare Interoperability Resources (FHIR) Genomics Reporting Implementation Guide, version 3 (also known as “FHIR Genomics”) for the structured communication of semantic objects typically appearing in real-world somatic testing reports. Materials and Methods: The GenomeX project team, part of the CodeX FHIR Accelerator, performed the following assessment: (1) gather a convenience sample of public somatic reports; (2) create a representative somatic report that includes a wide range of observations taken from the sample reports; and (3) structure the representative somatic report using the FHIR Genomics standard. Results: Attempted encodings were categorized into 1 of the 4 buckets: (1) full encoding possible (eg, DNA variants); (2) full encoding with potential variability (eg, therapeutic implications); (3) partial encoding (eg, genomic study details); and (4) not encoded (ie, FHIR Genomics has no explicit or acceptable semantic target, such as for coarsely granular pertinent negatives). In our sample somatic report, 47 semantic objects were noted, of which 87% had either full encoding or full encoding with potential variability. Conclusion: While dynamic real-world requirements, as exemplified by cancer genomics, often arise more rapidly than can be standardized, we conclude that the FHIR Genomics version 3 standard is sufficiently robust for the communication of current actionable somatic testing results.
- Open Access
Development and application of a computable genotype model in the GA4GH Variation Representation Specification
As the diversity of genomic variation data increases with our growing understanding of the role of variation in health and disease, it is critical to develop standards for precise inter-system exchange of these data for research and clinical applications. The Global Alliance for Genomics and Health (GA4GH) Variation Representation Specification (VRS) meets this need through a technical terminology and information model for disambiguating and concisely representing variation concepts. Here we discuss the recent Genotype model in VRS, which may be used to represent the allelic composition of a genetic locus. We demonstrate the use of the Genotype model and the constituent Haplotype model for the precise and interoperable representation of pharmacogenomic diplotypes, HGVS variants, and VCF records using VRS and discuss how this can be leveraged to enable interoperable exchange and search operations between assayed variation and genomic knowledgebases.
Open AccessDevelopment and application of a computable genotype model in the GA4GH Variation Representation Specification
As the diversity of genomic variation data increases with our growing understanding of the role of variation in health and disease, it is critical to develop standards for precise inter-system exchange of these data for research and clinical applications. The Global Alliance for Genomics and Health (GA4GH) Variation Representation Specification (VRS) meets this need through a technical terminology and information model for disambiguating and concisely representing variation concepts. Here we discuss the recent Genotype model in VRS, which may be used to represent the allelic composition of a genetic locus. We demonstrate the use of the Genotype model and the constituent Haplotype model for the precise and interoperable representation of pharmacogenomic diplotypes, HGVS variants, and VCF records using VRS and discuss how this can be leveraged to enable interoperable exchange and search operations between assayed variation and genomic knowledgebases.
- Open Access
Vaginal microbiome is associated with endometrial cancer grade and histology
Background The vaginal microbiome is an underexplored environment which may yield insights about endometrial cancer (EC) pathophysiology and serve as an early marker of disease. Our objective was to evaluate the preoperative vaginal microbiome in women undergoing hysterectomy for benign conditions and EC to identify patterns which could segregate benign disease from EC, and to assess if the microbiome distinguishes low-grade (LG) from high-grade (HG) histologies. Methods Vaginal microbiome samples were prospectively collected at the time of hysterectomy, and clinicopathologic data collected. Extracted DNA underwent shotgun metagenomics sequencing. Microbial diversity was calculated using the Shannon Index (α-diversity) and PERMANOVA (β-diversity). Hierarchical clustering was used to describe community state types (CST), which were then compared by microbial diversity and grade. Machine learning was utilized to assess the predictive value of grade and histology based on relative bacterial abundance. Results 61 patients participated: 1) benign gynecologic disease (n=11), 2) LG EC (n=30), and 3) HG EC (n=20). 40 (62.5%) were White, 22 (34.3%) were Black, and 37 (57.8%) were Hispanic. Both α- and β-diversity were associated with tumor grade (p□=□0.026 and p□=□0.035, respectively). Four CST were identified that associated with grade of disease (p=0.036). Different histologies demonstrated variation in CST even within tumor grades (p=0.017). Markers at the species level informed models that predicted benign vs cancer (AUC 0.878), HG versus benign (AUC=0.803), and HG versus LG (AUC=0.771) with high accuracy. Conclusions The vaginal microbiome segregates benign disease from EC, and is predictive of histology and grade, suggesting it may be an effective tool for screening.
Open AccessVaginal microbiome is associated with endometrial cancer grade and histology
Background The vaginal microbiome is an underexplored environment which may yield insights about endometrial cancer (EC) pathophysiology and serve as an early marker of disease. Our objective was to evaluate the preoperative vaginal microbiome in women undergoing hysterectomy for benign conditions and EC to identify patterns which could segregate benign disease from EC, and to assess if the microbiome distinguishes low-grade (LG) from high-grade (HG) histologies. Methods Vaginal microbiome samples were prospectively collected at the time of hysterectomy, and clinicopathologic data collected. Extracted DNA underwent shotgun metagenomics sequencing. Microbial diversity was calculated using the Shannon Index (α-diversity) and PERMANOVA (β-diversity). Hierarchical clustering was used to describe community state types (CST), which were then compared by microbial diversity and grade. Machine learning was utilized to assess the predictive value of grade and histology based on relative bacterial abundance. Results 61 patients participated: 1) benign gynecologic disease (n=11), 2) LG EC (n=30), and 3) HG EC (n=20). 40 (62.5%) were White, 22 (34.3%) were Black, and 37 (57.8%) were Hispanic. Both α- and β-diversity were associated with tumor grade (p□=□0.026 and p□=□0.035, respectively). Four CST were identified that associated with grade of disease (p=0.036). Different histologies demonstrated variation in CST even within tumor grades (p=0.017). Markers at the species level informed models that predicted benign vs cancer (AUC 0.878), HG versus benign (AUC=0.803), and HG versus LG (AUC=0.771) with high accuracy. Conclusions The vaginal microbiome segregates benign disease from EC, and is predictive of histology and grade, suggesting it may be an effective tool for screening.
- Open Access
- 1 December 2021
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 7 (7) , 1380-1389
Digital Pathology in Cameroon
PURPOSE: Cancer is becoming increasingly prevalent among the group of treatable diseases in African countries. There is a shortage of clinicians and pathologists available for cancer diagnosis and treatment. These limited resources must be efficiently used to maximize the number of patients treated. One of the critical factors in treatment efficiency is the correct and timely diagnosis of specimens by pathologists. However, there is currently a significant shortage of cancer care clinicians in Africa and an even more considerable shortage of pathologists. This article presents an example in which telepathology was used to mitigate the lack of pathologists in Cameroon. METHODS: The telepathology workaround was implemented in a district hospital based in Cameroon's Adamawa region, where a European surgeon provides cancer treatment. A small histology laboratory there is run by one histotechnologist who processes surgical biopsies into histology slides. As there are no pathologists on site, these slides are digitally scanned using a mobile phone and a whole slide imaging (WSI) scanner. The slides are then shared electronically with a volunteering pathologist in Europe who provides a diagnostic report. RESULTS: From 2018 to July 2019, specimens for 101 patients were photographed through an iPhone connected to a microscope eyepiece producing several individual images per specimen. From July 2019 to December 2020, slides from 282 patients were scanned using WSI and digitally transmitted. CONCLUSION: WSI on hematoxylin and eosin histology slides for remote diagnosis can increase cancer treatment efficacy and reduce overtreatment of tumors clinically suspicious for malignancy in under-resourced countries with a lack of pathologists.
- 1 December 2021
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 7 (7) , 1380-1389
Open AccessDigital Pathology in Cameroon
PURPOSE: Cancer is becoming increasingly prevalent among the group of treatable diseases in African countries. There is a shortage of clinicians and pathologists available for cancer diagnosis and treatment. These limited resources must be efficiently used to maximize the number of patients treated. One of the critical factors in treatment efficiency is the correct and timely diagnosis of specimens by pathologists. However, there is currently a significant shortage of cancer care clinicians in Africa and an even more considerable shortage of pathologists. This article presents an example in which telepathology was used to mitigate the lack of pathologists in Cameroon. METHODS: The telepathology workaround was implemented in a district hospital based in Cameroon's Adamawa region, where a European surgeon provides cancer treatment. A small histology laboratory there is run by one histotechnologist who processes surgical biopsies into histology slides. As there are no pathologists on site, these slides are digitally scanned using a mobile phone and a whole slide imaging (WSI) scanner. The slides are then shared electronically with a volunteering pathologist in Europe who provides a diagnostic report. RESULTS: From 2018 to July 2019, specimens for 101 patients were photographed through an iPhone connected to a microscope eyepiece producing several individual images per specimen. From July 2019 to December 2020, slides from 282 patients were scanned using WSI and digitally transmitted. CONCLUSION: WSI on hematoxylin and eosin histology slides for remote diagnosis can increase cancer treatment efficacy and reduce overtreatment of tumors clinically suspicious for malignancy in under-resourced countries with a lack of pathologists.
- Open Access
- 3 May 2021
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 156 (4) , 700-707
Wrong Tissue in Block
Objectives: Maintaining specimen identity during surgical pathology tissue processing is critical. Epic Beaker Laboratory Information System requires sequential scanning of specimen label and grossed blocks (block confirmation) to ensure specimen identity. We report our institution’s experience with wrong tissue in block (WTIB) grossing errors before and after adopting block confirmation. Methods: During the first 18 months of Beaker implementation, block confirmation was not required. We then mandated block confirmation for a 3-month period. To ensure compliance, we then built a “hard stop” feature that prevents scanning any unconfirmed blocks onto a packing list. We reviewed WTIB incidents pre- and postimplementation of these solutions. Results: Before using block confirmation, we had WTIB incidents involving 17 (0.043%) of 38,848 cases. When we mandated block confirmation use, we had WTIB involving 2 (0.043%) of 4,646 cases. After implementing the hard stop feature, we had WTIB incidents involving 2 (0.005%) of 42,411 cases. Overall, there was an 88.4% (0.043% vs 0.005%; P < .001) reduction in WTIB incidents using block confirmation with a hard stop. Conclusions: Beaker is a customizable platform that can be tailored to a laboratory’s workflow. By using barcoding, implementing custom-built features, and improving workflow protocols, we significantly reduced WTIB errors.
- 3 May 2021
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 156 (4) , 700-707
Open AccessWrong Tissue in Block
Objectives: Maintaining specimen identity during surgical pathology tissue processing is critical. Epic Beaker Laboratory Information System requires sequential scanning of specimen label and grossed blocks (block confirmation) to ensure specimen identity. We report our institution’s experience with wrong tissue in block (WTIB) grossing errors before and after adopting block confirmation. Methods: During the first 18 months of Beaker implementation, block confirmation was not required. We then mandated block confirmation for a 3-month period. To ensure compliance, we then built a “hard stop” feature that prevents scanning any unconfirmed blocks onto a packing list. We reviewed WTIB incidents pre- and postimplementation of these solutions. Results: Before using block confirmation, we had WTIB incidents involving 17 (0.043%) of 38,848 cases. When we mandated block confirmation use, we had WTIB involving 2 (0.043%) of 4,646 cases. After implementing the hard stop feature, we had WTIB incidents involving 2 (0.005%) of 42,411 cases. Overall, there was an 88.4% (0.043% vs 0.005%; P < .001) reduction in WTIB incidents using block confirmation with a hard stop. Conclusions: Beaker is a customizable platform that can be tailored to a laboratory’s workflow. By using barcoding, implementing custom-built features, and improving workflow protocols, we significantly reduced WTIB errors.
- 1 April 2021
- Published by Elsevier in Neuroscience Letters
- Vol. 751, 135829
Enrichment of the erythrocyte miR-451a in brain extracellular vesicles following impairment of the blood-brain barrier
- 1 April 2021
- Published by Elsevier in Neuroscience Letters
- Vol. 751, 135829
Enrichment of the erythrocyte miR-451a in brain extracellular vesicles following impairment of the blood-brain barrier
- Open Access
- 1 January 2021
- Published by Science Diffusion Ltd
vcf2fhir: Bridging the Gap Between Genomics and Healthcare
On molecular scales, the responses of our bodies to particular medical treatments are deeply engrained in our unique genetic codes. Yet so far, the advanced computer science technologies used to study patient responses and molecular-scale mechanisms have remained entirely independent from each other. Now, Dr Robert Dolin of Elimu Informatics, Dr Srikar Chamala at the University of Florida, and Dr Gil Alterovitz at Brigham and Women’s Hospital, address this issue through vcf2fhir: a resource capable of converting between the file formats used by both fields. Through future improvements, his team’s approach could soon transform the ways in which crucial clinical decisions are made.
- 1 January 2021
- Published by Science Diffusion Ltd
Open Accessvcf2fhir: Bridging the Gap Between Genomics and Healthcare
On molecular scales, the responses of our bodies to particular medical treatments are deeply engrained in our unique genetic codes. Yet so far, the advanced computer science technologies used to study patient responses and molecular-scale mechanisms have remained entirely independent from each other. Now, Dr Robert Dolin of Elimu Informatics, Dr Srikar Chamala at the University of Florida, and Dr Gil Alterovitz at Brigham and Women’s Hospital, address this issue through vcf2fhir: a resource capable of converting between the file formats used by both fields. Through future improvements, his team’s approach could soon transform the ways in which crucial clinical decisions are made.
- Open Access
- 1 January 2021
- Published by Elsevier in Academic Pathology
- Vol. 8
Pathology Informatics and Robotics Strategies for Improving Efficiency of COVID-19 Pooled Testing
- 1 January 2021
- Published by Elsevier in Academic Pathology
- Vol. 8
Open AccessPathology Informatics and Robotics Strategies for Improving Efficiency of COVID-19 Pooled Testing
- Open Access
- 30 November 2020
- Published by Oxford University Press (OUP) in JAMIA Open
- Vol. 3 (4) , 530-535
Informatics driven quality improvement in the modern histology lab
Laboratory Information Systems (LIS) and data visualization techniques have untapped potential in anatomic pathology laboratories. Pre-built functionalities of LIS do not address all the needs of a modern histology laboratory. For instance, “Go live” is not the end of LIS customization, but just the beginning. After closely evaluating various histology lab workflows, we implemented several custom data analytics dashboards and additional LIS functionalities to monitor and address weaknesses. Herein, we present our experience in LIS and data-tracking solutions that improved trainee education, slide logistics, staffing/instrumentation lobbying, and task tracking. The latter was addressed through the creation of a novel “status board” akin to those seen in inpatient wards. These use-cases can benefit other histology laboratories.
- 30 November 2020
- Published by Oxford University Press (OUP) in JAMIA Open
- Vol. 3 (4) , 530-535
Open AccessInformatics driven quality improvement in the modern histology lab
Laboratory Information Systems (LIS) and data visualization techniques have untapped potential in anatomic pathology laboratories. Pre-built functionalities of LIS do not address all the needs of a modern histology laboratory. For instance, “Go live” is not the end of LIS customization, but just the beginning. After closely evaluating various histology lab workflows, we implemented several custom data analytics dashboards and additional LIS functionalities to monitor and address weaknesses. Herein, we present our experience in LIS and data-tracking solutions that improved trainee education, slide logistics, staffing/instrumentation lobbying, and task tracking. The latter was addressed through the creation of a novel “status board” akin to those seen in inpatient wards. These use-cases can benefit other histology laboratories.
- Open Access
- 24 November 2020
- Published by Oxford University Press (OUP) in JAMIA Open
- Vol. 3 (4) , 523-529
Optimizing COVID-19 testing capabilities and clinical management using pathology informatics
Coronavirus disease 2019, first reported in China in late 2019, has quickly spread across the world. The outbreak was declared a pandemic by the World Health Organization on March 11, 2020. Here, we describe our initial efforts at the University of Florida Health for processing of large numbers of tests, streamlining data collection, and reporting data for optimizing testing capabilities and superior clinical management. Specifically, we discuss clinical and pathology informatics workflows and informatics instruments which we designed to meet the unique challenges of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing. We hope these results benefit institutions preparing to implement SARS-CoV-2 testing.
- 24 November 2020
- Published by Oxford University Press (OUP) in JAMIA Open
- Vol. 3 (4) , 523-529
Open AccessOptimizing COVID-19 testing capabilities and clinical management using pathology informatics
Coronavirus disease 2019, first reported in China in late 2019, has quickly spread across the world. The outbreak was declared a pandemic by the World Health Organization on March 11, 2020. Here, we describe our initial efforts at the University of Florida Health for processing of large numbers of tests, streamlining data collection, and reporting data for optimizing testing capabilities and superior clinical management. Specifically, we discuss clinical and pathology informatics workflows and informatics instruments which we designed to meet the unique challenges of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing. We hope these results benefit institutions preparing to implement SARS-CoV-2 testing.